Review ArticleReviews and Contemporary Updates
Choosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to Know
Alpesh Amin
Ochsner Journal December 2016, 16 (4) 531-541;
Alpesh Amin
Department of Medicine, Hospitalist Program, University of California, Irvine School of Medicine, Irvine, CA
MD, MBAREFERENCES
- ↵
- Connolly SJ,
- Ezekowitz MD,
- Yusuf S,
- et al.
- ↵
- Granger CB,
- Alexander JH,
- McMurray JJ,
- et al.
- ↵
- Patel MR,
- Mahaffey KW,
- Garg J,
- et al.
- ↵
- Giugliano RP,
- Ruff CT,
- Braunwald E,
- et al.
- ↵
- Agnelli G,
- Buller HR,
- Cohen A,
- et al.
- Hokusai-VTE Investigators, ,
- Büller HR,
- Décousus H,
- Grosso MA,
- et al.
- ↵
- Schulman S,
- Kearon C,
- Kakkar AK,
- et al.
- ↵
- Prins MH,
- Lensing AW,
- Bauersachs R,
- et al.
- ↵
- Hirsh J,
- Fuster V,
- Ansell J,
- Halperin JL;
- ↵Pradaxa (dabigatran etexilate mesylate). Full Prescribing Information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2015. http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. Accessed August 4, 2016.
- ↵Xarelto (rivaroxaban) tablets. Full Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals, USA; 2015 https://www.xareltohcp.com/shared/product/xarelto/prescribing-information.pdf. Accessed August 4, 2016.
- ↵Eliquis (apixaban) tablets for oral use. Full Prescribing Information. Princeton, NJ and New York: Bristol-Myers Squibb Company and Pfizer; 2015. https://www.eliquis.com/eliquis/servlet/servlet.FileDownload?file=00Pi000000GM6ILEA1. Accessed August 4, 2016.
- ↵Savaysa (edoxaban) tablets for oral use. Full Prescribing Information. Parsippany, NJ: Daiichi Sankyo; 2016. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206316lbl.pdf. Accessed October 10, 2016.
- ↵
- Ageno W,
- Gallus AS,
- Wittkowsky A,
- Crowther M,
- Hylek EM,
- Palareti G
- ↵
- January CT,
- Wann LS,
- Alpert JS,
- et al.
- ↵
- EINSTEIN Investigators
- Bauersachs R,
- Berkowitz SD,
- Brenner B,
- et al.
- ↵
- EINSTEIN-PE Investigators
- Büller HR,
- Prins MH,
- Lensin AW,
- et al.
- ↵
- Pfeilschifter W,
- Luger S,
- Brunkhorst R,
- Lindhoff-Last E,
- Foerch C.
- ↵
- Clemens A,
- Noack H,
- Brueckmann M,
- Lip GY.
- ↵
- Marzec LN,
- Gosch KL,
- Chan PS,
- Ting HH,
- Shah ND,
- Maddox TM.
- ↵
- Cohen E,
- Nardi Y,
- Krause I,
- et al.
- ↵
- Miyamoto K,
- Aiba T,
- Arihiro S,
- et al.
- ↵
- Nielsen PB,
- Lane DA,
- Rasmussen LH,
- Lip GY,
- Larsen TB.
- ↵
- Eisen A,
- Giugliano RP,
- Ruff CT,
- et al.
- ↵
- Focks JJ,
- Brouwer MA,
- Wojdyla DM,
- et al.
- ↵
- Goldhaber SZ,
- Eriksson H,
- Kakkar A,
- et al.
- ↵
- Heidbuchel H,
- Verhamme P,
- Alings M,
- et al.
- Camm AJ,
- Lip GY,
- De Caterina R,
- et al.
- ↵
- Pisters R,
- Lane DA,
- Nieuwlaat R,
- de Vos CB,
- Crijns HJ,
- Lip GY.
- ↵
- Apostolakis S,
- Lane DA,
- Buller H,
- Lip GY.
- ↵
- Poli D,
- Antonucci E,
- Testa S,
- Tosetto A,
- Ageno W,
- Palareti G
- ↵
- Lip GY,
- Nieuwlaat R,
- Pisters R,
- Lane DA,
- Crijns HJ.
- ↵
- Oldgren J,
- Alings M,
- Darius H,
- et al.
- ↵
- Ruff CT,
- Giugliano RP,
- Braunwald E,
- et al.
- ↵
- Skaistis J,
- Tagami T.
- ↵
- Sharma M,
- Cornelius VR,
- Patel JP,
- Davies JG,
- Molokhia M.
- ↵
- Lauffenburger JC,
- Rhoney DH,
- Farley JF,
- Gehi AK,
- Fang G.
- ↵
- Connolly SJ,
- Ezekowitz MD,
- Yusuf S,
- Reilly PA,
- Wallentin L;
- ↵
- Hohnloser SH,
- Oldgren J,
- Yang S,
- et al.
- ↵
- Douxfils J,
- Buckinx F,
- Mullier F,
- et al.
- ↵
- Larsen TB,
- Rasmussen LH,
- Gorst-Rasmussen A,
- et al.
- ↵
- Loffredo L,
- Perri L,
- Violi F.
- ↵
- Alexander JH,
- Lopes RD,
- James S,
- et al.
- ↵
- Mega JL,
- Braunwald E,
- Wiviott SD,
- et al.
- ↵
- Krantz MJ,
- Kaul S.
- ↵
- Oldgren J,
- Budaj A,
- Granger CB,
- et al.
- ↵
- Levy JH,
- Ageno W,
- Chan NC,
- Crowther M,
- Verhamme P,
- Weitz JI;
- ↵
- Alikhan R,
- Rayment R,
- Keeling D,
- et al.
- ↵
- Weitz JI,
- Pollack CV Jr.
- ↵Praxbind (idarucizumab). Full Prescribing Information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2015. http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Praxbind/Praxbind.pdf. Accessed August 4, 2016.
- ↵
- Pollack CV Jr.,
- Reilly PA,
- Eikelboom J,
- et al.
- ↵
- Laulicht B,
- Bakhru S,
- Lee C,
- et al.
- Bakhru S,
- Laulicht B,
- Jiang X,
- et al.
- ↵
- Ansell JE,
- Bakhru SH,
- Laulicht BE,
- et al.
- Crowther M,
- Mathur V,
- Kitt M,
- et al.
- Gold AM,
- Crowther M,
- Levy G,
- et al.
- ↵
- Siegal DM,
- Curnutte JT,
- Connolly SJ,
- et al.
- ↵Portola Pharmaceuticals announces biologics license application for Andexanet Alfa accepted for review by FDA [press release]. South San Francisco, CA: Portola Pharmaceuticals; Feb 17, 2016. http://investors.portola.com/phoenix.zhtml?c=198136&p=irol-newsroomArticle&ID=2140255. Accessed April 15, 2016.
- ↵
- Zahir H,
- Brown KS,
- Vandell AG,
- et al.
- ↵
- Dzik WH.
- ↵
- Budnitz DS,
- Lovegrove MC,
- Shehab N,
- Richards CL.
- ↵
- Amin A,
- Jing Y,
- Trocio J,
- Lin J,
- Lingohr-Smith M,
- Graham J.
- ↵
- Amin A,
- Bruno A,
- Trocio J,
- Lin J,
- Lingohr-Smith M.
- ↵
- ↵
- Laliberté F,
- Nelson WW,
- Schein J,
- Rondeau-Leclaire J,
- Lefebvre P,
- Duh MS.
- ↵
- Laliberté F,
- Bookhart BK,
- Nelson WW,
- et al.
- ↵
- Böttger B,
- Thate-Waschke IM,
- Bauersachs R,
- Kohlmann T,
- Wilke T.
- ↵
- Martinez C,
- Katholing A,
- Wallenhorst C,
- Freedman SB.
- ↵
- Prins MH,
- Bamber L,
- Cano SJ,
- et al.
In this issue
Choosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to Know
Alpesh Amin
Ochsner Journal Dec 2016, 16 (4) 531-541;
Jump to section
- Article
- Abstract
- INTRODUCTION
- METHODS
- ANTICOAGULANTS AND THE COAGULATION CASCADE
- DOSING CONSIDERATIONS AND RISK FACTORS FOR BLEEDING
- RENAL IMPAIRMENT: PATIENT EXAMPLE 1
- DRUG-DRUG INTERACTIONS: PATIENT EXAMPLE 2
- HIGH RISK FOR BLEEDING: PATIENT EXAMPLE 3
- PRIOR HISTORY OF MYOCARDIAL INFARCTION OR ACUTE CORONARY SYNDROME: PATIENT EXAMPLE 4
- PATIENTS WHO ARE BLEEDING: PATIENT EXAMPLE 5
- ECONOMIC CONSIDERATIONS
- CONCLUSION
- ACKNOWLEDGMENTS
- REFERENCES
- Figures & Data
- References
- Info & Metrics
Cited By...
- No citing articles found.